Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial

NCT04428554 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT04428554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04428554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial
Lead sponsor
Institut Claudius Regaud
Phase
Phase 2
Overall status
Recruiting
Start date
June 30, 2020
Completion date
July 31, 2031
Enrollment
130 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial bladder cancer